|
|
|
|
LEADER |
00000cam a22000004a 4500 |
001 |
11812424 |
006 |
m o d |
007 |
cr cnu---unuuu |
008 |
060619s2005 enka ob 001 0 eng d |
005 |
20240717165547.8 |
010 |
|
|
|z 2005012018
|
016 |
7 |
|
|a 101263888
|2 DNLM
|
019 |
|
|
|a 71354972
|a 76972155
|a 171123807
|a 252516285
|a 519483591
|a 613339041
|a 647503012
|a 756843679
|a 994844812
|a 1034922425
|a 1035690310
|a 1044157999
|a 1044564053
|a 1056311056
|a 1056383932
|a 1074303382
|a 1077882159
|a 1079891962
|a 1087030709
|a 1097296619
|a 1099559149
|a 1119511215
|a 1125413037
|a 1125469096
|a 1136294307
|a 1136329238
|a 1167557501
|a 1175671393
|a 1241940673
|
020 |
|
|
|a 9780511610769
|q (electronic bk.)
|
020 |
|
|
|a 0511610769
|q (electronic bk.)
|
020 |
|
|
|a 0511137575
|q (electronic bk.)
|
020 |
|
|
|a 9780511137570
|q (electronic bk.)
|
020 |
|
|
|a 0511135408
|q (electronic bk. ;
|q Adobe Reader)
|
020 |
|
|
|a 9780511135408
|q (electronic bk. ;
|q Adobe Reader)
|
020 |
|
|
|a 0521854962
|
020 |
|
|
|a 9780521854962
|
020 |
|
|
|a 0511133995
|q (electronic bk. ;
|q Adobe Reader)
|
020 |
|
|
|a 9780511133992
|q (electronic bk. ;
|q Adobe Reader)
|
020 |
|
|
|a 0511167768
|
020 |
|
|
|a 9780511167768
|
020 |
|
|
|a 0511134436
|q (electronic bk.)
|
020 |
|
|
|a 9780511134432
|q (electronic bk.)
|
020 |
|
|
|a 9786610437115
|
020 |
|
|
|a 6610437114
|
020 |
|
|
|a 9780521708883
|q (paperback)
|
020 |
|
|
|a 0521708885
|
020 |
|
|
|a 1280437111
|
020 |
|
|
|a 9781280437113
|
020 |
|
|
|a 0511311907
|
020 |
|
|
|a 9780511311901
|
020 |
|
|
|a 1107155185
|
020 |
|
|
|a 9781107155183
|
024 |
3 |
|
|a 9780511137570
|
024 |
3 |
|
|a 9780521854962
|
035 |
|
|
|a (OCoLC)70135191
|z (OCoLC)71354972
|z (OCoLC)76972155
|z (OCoLC)171123807
|z (OCoLC)252516285
|z (OCoLC)519483591
|z (OCoLC)613339041
|z (OCoLC)647503012
|z (OCoLC)756843679
|z (OCoLC)994844812
|z (OCoLC)1034922425
|z (OCoLC)1035690310
|z (OCoLC)1044157999
|z (OCoLC)1044564053
|z (OCoLC)1056311056
|z (OCoLC)1056383932
|z (OCoLC)1074303382
|z (OCoLC)1077882159
|z (OCoLC)1079891962
|z (OCoLC)1087030709
|z (OCoLC)1097296619
|z (OCoLC)1099559149
|z (OCoLC)1119511215
|z (OCoLC)1125413037
|z (OCoLC)1125469096
|z (OCoLC)1136294307
|z (OCoLC)1136329238
|z (OCoLC)1167557501
|z (OCoLC)1175671393
|z (OCoLC)1241940673
|
035 |
|
9 |
|a (OCLCCM-CC)70135191
|
037 |
|
|
|a FB361420-BB50-4333-B2CB-30AE73DAD17E
|b OverDrive, Inc.
|n http://www.overdrive.com
|
040 |
|
|
|a N$T
|b eng
|e pn
|c N$T
|d YDXCP
|d OCLCQ
|d FTU
|d OCLCQ
|d EBLCP
|d NRU
|d TEFOD
|d MT4IT
|d W2U
|d E7B
|d AZU
|d IDEBK
|d OCLCQ
|d OCLCF
|d OCLCQ
|d DEBSZ
|d OCLCQ
|d TEFOD
|d OCLCQ
|d OTZ
|d OCLCQ
|d UAB
|d STF
|d OCLCQ
|d COCUF
|d CEF
|d OCLCA
|d OCLCQ
|d FVL
|d YOU
|d CANPU
|d BRX
|d OCLCO
|d OCLCA
|d AGLDB
|d AU@
|d OCLCO
|d CNTRU
|d OCLCO
|d OCLCQ
|d A6Q
|d KIJ
|d SFB
|d OCLCA
|d LUN
|d INARC
|d EZC
|d UKAHL
|d OCLCQ
|d OCLCO
|d QGK
|
049 |
|
|
|a MAIN
|
050 |
|
4 |
|a HD9665.5
|b .E85 2005eb
|
060 |
|
4 |
|a 2005 O-341
|
060 |
|
4 |
|a QV 736
|b E848 2005
|
072 |
|
7 |
|a BUS
|x 070130
|2 bisacsh
|
084 |
|
|
|a 85.02
|2 bcl
|
245 |
0 |
0 |
|a Ethics and the pharmaceutical industry /
|c edited by Michael A. Santoro, Thomas M. Gorrie.
|
260 |
|
|
|a Cambridge ;
|a New York, NY :
|b Cambridge University Press,
|c 2005.
|
300 |
|
|
|a 1 online resource (xxxiv, 492 pages) :
|b illustrations
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
504 |
|
|
|a Includes bibliographical references and index.
|
505 |
0 |
|
|a Drug research: between ethical demands and economic constraints / Jürgen Drews -- Emerging international norms for clinical testing: good clinical trial practice / Juhana E. Idänpään-Heikkilä, Sev Fluss -- The regulatory and ethical challenges of pediatric research / M. Dianne Murphy, Sara F. Goldkind -- Including children in research: participation or exploitation? / Robert M. Nelson -- Racial and ethnic inclusiveness in clinical trials / Valentine J. Burroughs -- The rights of patients to participate in clinical research / Glenna M. Crooks -- How should government regulate stem-cell research? views from a scientist-legislator / Rush Holt -- Ethics and prescribing: the clinician's perspective / Charles L. Bardes -- The regulation of prescription drug promotion / Thomas Abrams.
|
505 |
0 |
|
|a Direct-to-consumer advertising of prescription drugs: a policy dilemma / Meredith B. Rosenthal, Julie M. Donohue -- Off-label communications and prescription drugs / Schott D. Danzis -- The need for better health information: advancing the informed patient in Europe / Don E. Detmer, Peter Singleton, Scott C. Ratzan -- Who should get access to which drugs? an ethical template for pharmacy benefits / Norman Daniels, James E. Sabin, J. Russell Teagarden -- The application of cost-effectiveness and cost-benefit analysis to pharmaceuticals / Joel W. Hay -- Intellectual property rights, access to life-enhancing drugs, and corporate moral responsibilities / Patricia H. Werhande, Michael E. Gorman.
|
505 |
0 |
|
|a A future agenda for government-industry relations / William C. Weldon -- AIDS activism and the pharmaceutical industry / Martin Delaney -- The campaign against innovation / Sidney Taurel -- Third world perspectives on global pharmaceutical access / James Thuo Gathii -- The promise of vaccines and the influenza vaccine shortage of 2004: public and private partnerships / Gary R. Noble -- Evolving approaches to healthcare challenges / Thomas M. Gorrie -- Property rights in crisis: managers and rescue / Nien-hê Hsieh -- Blurring the lines: public and private partnerships addressing global health / William H. Foege -- Renegotiating the grand bargain: balancing prices, profits, people, and principles / Edward Greg Koski.
|
588 |
0 |
|
|a Print version record.
|
520 |
|
|
|a This book is a discussion of the ethical dilemmas of drug industry behavior. It examines such aspects as the role of intellectual property rights and patent protection, the moral and economic requisites of research and clinical trials, drug pricing, and marketing.
|
546 |
|
|
|a English.
|
650 |
|
0 |
|a Pharmaceutical industry.
|
650 |
|
0 |
|a Drugs
|x Marketing
|x Moral and ethical aspects.
|
650 |
|
0 |
|a Drugs
|x Research
|x Moral and ethical aspects.
|
650 |
|
0 |
|a Medical innovations
|x Social aspects.
|0 http://id.loc.gov/authorities/subjects/sh85082947
|
650 |
|
0 |
|a Social responsibility of business.
|0 http://id.loc.gov/authorities/subjects/sh90005735
|
650 |
1 |
2 |
|a Drug Industry
|x ethics.
|
650 |
1 |
2 |
|a Drug Industry
|x organization & administration.
|
650 |
2 |
2 |
|a Ethics, Business.
|
650 |
2 |
2 |
|a Social Responsibility.
|
650 |
2 |
2 |
|a Technology, Pharmaceutical
|x ethics.
|
650 |
|
7 |
|a BUSINESS & ECONOMICS
|x Industries
|x Pharmaceutical & Biotechnology.
|2 bisacsh
|
650 |
|
7 |
|a Drugs
|x Marketing
|x Moral and ethical aspects.
|2 fast
|0 (OCoLC)fst00898841
|
650 |
|
7 |
|a Drugs
|x Research
|x Moral and ethical aspects.
|2 fast
|0 (OCoLC)fst00898905
|
650 |
|
7 |
|a Medical innovations
|x Social aspects.
|2 fast
|0 (OCoLC)fst01014193
|
650 |
|
7 |
|a Pharmaceutical industry.
|2 fast
|0 (OCoLC)fst01060129
|
650 |
|
7 |
|a Social responsibility of business.
|2 fast
|0 (OCoLC)fst01122851
|
650 |
1 |
7 |
|a Farmaceutische industrie.
|2 gtt
|
650 |
1 |
7 |
|a Ethiek.
|2 gtt
|
655 |
|
4 |
|a Electronic books.
|
700 |
1 |
|
|a Santoro, Michael A.
|0 http://id.loc.gov/authorities/names/n99282217
|
700 |
1 |
|
|a Gorrie, Thomas M.
|0 http://id.loc.gov/authorities/names/n2005031443
|
776 |
0 |
8 |
|i Print version:
|t Ethics and the pharmaceutical industry.
|d Cambridge ; New York, NY : Cambridge University Press, 2005
|z 0521854962
|w (DLC) 2005012018
|w (OCoLC)60028983
|
903 |
|
|
|a HeVa
|
929 |
|
|
|a oclccm
|
999 |
f |
f |
|i f40e06db-1b07-5ddf-bf57-aa18c16afb48
|s 2e21ada8-270f-5624-85a2-a3155984bea9
|
928 |
|
|
|t Library of Congress classification
|a HD9665.5 .E85 2005eb
|l Online
|c UC-FullText
|u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=e000xna&AN=156553
|z eBooks on EBSCOhost
|g ebooks
|i 12233230
|